Related Experiment Video

Updated: May 13, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Protein kinase inhibitors against malignant lymphoma

Osmond J D'Cruz1, Fatih M Uckun

  • 1Children's Hospital Los Angeles, Children's Center for Cancer and Blood Diseases, Los Angeles, CA 90027, USA.

Expert Opinion on Pharmacotherapy
|March 19, 2013
PubMed
Abstract

Insights

Novel tyrosine kinase inhibitors (TKIs) show significant antitumor activity in B-cell lymphomas. Identifying patient-specific markers is key for successful targeted therapy and personalized treatment strategies.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Background:

  • Tyrosine kinases (TKs) regulate lymphoid cell functions; their deregulation drives B-cell malignancies.
  • Targeted TK inhibitors (TKIs) are emerging as treatments for relapsed/refractory B-cell lymphomas.
  • TKIs target oncogenic TKs, affecting signaling pathways, apoptosis, and the tumor microenvironment.

Purpose of the Study:

  • To review the clinical outcomes of novel TKIs in B-cell lymphomas.
  • To assess the efficacy of TKIs in relapsed or refractory disease.
  • To highlight the importance of molecular markers for TKI therapy.

Main Methods:

  • Review of published clinical studies and conference abstracts.
  • Analysis of clinical outcomes data for various TKIs.
  • Focus on TKIs targeting specific oncogenic tyrosine kinases.

Main Results:

  • TKIs demonstrate robust antitumor activity in B-cell lymphomas.
  • Clinical success is linked to specific oncogenic TK deregulation.
  • Identifying molecular and clinical markers is crucial for patient selection.

Conclusions:

  • Targeting deregulated TKs with TKIs yields significant antitumor responses in B-cell lymphomas.
  • Personalized therapy requires reliable markers to identify responsive patient cohorts.
  • Further research into signaling pathways will uncover new targets and therapeutic options.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...